Safety Study of AMG 531 in Japanese Subjects With ITP

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Clinical Trial

Official title:
An Open Label Phase 2 Study Evaluating the Safety of Starting Dose of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.

Clinical Trial Description

The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Purpura
Purpura, Thrombocytopenic
Thrombocytopenia
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Thrombocytosis

Clinical Trial Details

NCT number	NCT00305435
Study type	Interventional
Source	Kyowa Hakko Kirin Company, Limited
Contact
Status	Completed
Phase	Phase 2
Start date	February 2006
Completion date	November 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00454857` - Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)	N/A
Completed	`NCT00515203` - Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects	Phase 1/Phase 2
Completed	`NCT01444417` - Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients	Phase 3
Completed	`NCT00415532` - Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura	Phase 3